
Mingnan Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5784579/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. Journal of Controlled Release, 2022, 349, 425-433.	9.9	2
2	Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases. Frontiers in Immunology, 2021, 12, 645699.	4.8	18
3	Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity. Journal of Controlled Release, 2020, 328, 653-664.	9.9	2
4	Critical reviews of immunotheranostics. Theranostics, 2020, 10, 7403-7405.	10.0	3
5	Depletion of PD-1-positive cells ameliorates autoimmune disease. Nature Biomedical Engineering, 2019, 3, 292-305.	22.5	48
6	Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo. Biomaterials, 2018, 182, 92-103.	11.4	11
7	An Albumin-binding Polypeptide Both Targets Cytotoxic T Lymphocyte Vaccines to Lymph Nodes and Boosts Vaccine Presentation by Dendritic Cells. Theranostics, 2018, 8, 223-236.	10.0	27
8	Engineering of a self-adjuvanted iTEP-delivered CTL vaccine. Acta Pharmacologica Sinica, 2017, 38, 914-923.	6.1	7
9	An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional I±PD-1 Nanoparticle. Molecular Pharmaceutics, 2017, 14, 1494-1500.	4.6	26
10	Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface. Molecular Pharmaceutics, 2017, 14, 3312-3321.	4.6	7
11	A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers. Theranostics, 2016, 6, 666-678.	10.0	11
12	An iTEP-salinomycin nanoparticle that specifically and effectively inhibits metastases of 4T1 orthotopic breast tumors. Biomaterials, 2016, 93, 1-9.	11.4	29
13	Discovery of a ¹⁹ F MRI sensitive salinomycin derivative with high cytotoxicity towards cancer cells. Chemical Communications, 2016, 52, 5136-5139.	4.1	39
14	Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers. Journal of Drug Targeting, 2016, 24, 328-339.	4.4	36
15	Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. Journal of Controlled Release, 2015, 208, 52-58.	9.9	50
16	Gene-Directed Enzyme Prodrug Therapy. AAPS Journal, 2015, 17, 102-110.	4.4	122
17	iTEP Nanoparticle-Delivered Salinomycin Displays an Enhanced Toxicity to Cancer Stem Cells in Orthotopic Breast Tumors. Molecular Pharmaceutics, 2014, 11, 2703-2712.	4.6	46
18	Abstract 2816: Immune-tolerant elastin-like polypeptide (iTEP) particles promote peptide vaccine presentation by dendritic cells 2014		0

presentation by dendritic cells. , 2014, , .

Mingnan Chen

#	Article	IF	CITATIONS
19	NANOSCALE SELF-ASSEMBLY FOR DELIVERY OF THERAPEUTICS AND IMAGING AGENTS. Technology and Innovation, 2011, 13, 5-25.	0.2	4
20	Injectable intratumoral depot of thermally responsive polypeptide–radionuclide conjugates delays tumor progression in a mouse model. Journal of Controlled Release, 2010, 144, 2-9.	9.9	102
21	Self-assembling chimeric polypeptide–doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nature Materials, 2009, 8, 993-999.	27.5	532
22	The convergent roles of tapasin and HLA-DM in antigen presentation. Trends in Immunology, 2008, 29, 141-147.	6.8	39
23	Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection. EMBO Journal, 2007, 26, 1681-1690.	7.8	152
24	A Characterization of the Lumenal Region of Human Tapasin Reveals the Presence of Two Structural Domains. Biochemistry, 2002, 41, 14539-14545.	2.5	14